

Company Overview

Karyosoft is a secure, simple to use in-house genomics data management, analytics and visualization platform empowers biologists to improve R&D efficiency and accelerate innovations in agrigenomics and life sciences enterprises. Karyosoft has been proven to ensure higher data integrity (no data loss), save time (months vs days), and accelerate innovations.

Problem or Market Opportunity

In life sciences, with the availability of cheaper sequencing technologies, the biologists generate huge amounts of genomics data each year from other organisms which are larger than the data stored by YouTube and Twitter, to improve crops, animal, and human health. The problem is that these biologists, who typically lack coding skills, spend 25% to 70% of their time on data preparation due to lack of in-house tools and no easy mechanism to combine both public and private data. This situation lowers R&D efficiency and costs organizations millions of dollars and delays innovation.

Technical & Competitive Advantage

There are desktop-based solutions such as Geneious, CLC Genomics, Sequencher (commercial), web-based solutions such as DNA Nexus, Seven Bridges (commercial); Galaxy, UCSC Browser (public) and genomics CROs Sequencing facilities (Public and commercial); NR Gene, Eurofins (commercial). However, Karyosoft focuses exclusively on in-house genomics data management, analytics and visualization complementing our competitors; Karyosoft combines the benefits of web-based solutions for data security, cloud agnostic, for non-programming life scientists, and anywhere, anytime and on any device access to get genomics insights quickly combining both public and private data.

Regulatory Strategy & Intellectual Property

Karyosoft maintains algorithms as a trade secret.

Key Milestones

Q/YYYY	Objective	Milestone Description
Q3 2023	Traction	Close minimum of 2 clients through direct sales; increase leads by attending minimum of one conference
Q4 2023	Product Improvement	Add 2 new capabilities in our current platform
Q1 2024	Traction	Close minimum of 2 new clients for channel partnerships

Capitalization History

Year	Grant or Equity Type	Description	Amount
2018, 2019	Equity	PRF-Ag-Celerator, EPFF, ComebackCapital Bowl	\$220,000
2020	Equity	Health Wildcatters Accelerator	\$30,000
2018, 2019, 2023	Grants	ISBDC-INTAP, NSF-ICorps, IEDC	\$65,000

Current Round, Terms, and Use of Proceeds

Karyosoft is looking to raise \$500,000 in convertible notes or SAFE which will give us a 12-18 months runway. We are aiming to close this round by Dec 2023. The proceeds will be used for the following: 40% in R&D; 46% in sales and marketing and 15% in overhead. Karyosoft has already generated \$23K+ revenue, closed 2 clients, 3 channel partnership with AWS marketplace, NVIDIA and Google for startups, 4 pilots and 2 channels partnerships in pipeline. Secured \$250,000 diluted investments and \$65,000 undiluted funding. Health Wildcatters Accelerator alum, gBETA alum, showcased at 20+ national and international events; 25+ Press releases and podcasts; MIRA nominee (3 years); "30 startups to watch" by world AgriTech and 2022 Best of Carmel Award.

Key Team Members and Advisors

Rajesh Perianayagam Ph.D., Founder and CEO (FT) has three decades of experience in biology, genetics, genomics, software and business development and sales. He has extensive experience managing multi-million-dollar programs at Dow AgroSciences, and multi-billion-dollar clients at Roche Diagnostics, which led him to founding Karyosoft;

Ramesh Dharmaraj, CIO has more than 2 decades of experience in software industries and also AWS cloud practitioner

Vinothraj Sekar, CTO has more than a decade of experiences in data science and software development.

In addition, we have 4+ life sciences, genomics, Agri-data sciences and investment advisors.